EQS-News

Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure 07.05.2026, 13:50 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Advaita Bio / Key word(s): Product Launch
Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

07.05.2026 / 13:50 CET/CEST
The issuer is solely responsible for the content of this announcement.


GPU-Accelerated Platform Unifies Fragmented Workflows, Turning Weeks of Analysis into Minutes

ANN ARBOR, Mich., May 7, 2026 /PRNewswire/ -- Advaita Bio today announced the launch of iSCanGuide, a cloud-based platform engineered to transform large-scale single-cell and spatial transcriptomics datasets into biologically meaningful results. Built on 20 years of validated science, the platform is integrated with Advaita's flagship platform, iPathwayGuide, replacing fragmented workflows with a unified, GPU-powered discovery environment.

Advaita Logo

Single-cell and spatial transcriptomics generate complex datasets — but most researchers are still stitching together fragmented tools to analyze them, writing custom scripts, exporting between platforms, and losing weeks to manual workflows. iSCanGuide eliminates that bottleneck with a unified, GPU-accelerated environment that turns what used to take weeks into minutes, built on the same validated science that underpins Advaita's pathway analysis platform, trusted by over 13,000 researchers worldwide.

"Researchers are drowning in data and starving for insight," said Mike Mattacola, CEO of Advaita Bio. "iSCanGuide collapses what used to be a weeks-long manual process into minutes — from count matrices to annotated cell types, spatial context, and mechanistic pathway analysis in a single platform."

Key Features & Compatibility:

  • Real-Time Interaction: GUI-driven, zero-code interface with multiple navigation modes — accessible enough for first-time users, powerful for expert analysis.
  • Standardized Best-Practice Workflows: Ensure reproducibility and consistency across single-cell and spatial transcriptomics experiments with standardized, validated analysis pipelines.
  • Single-Cell Transcriptomics Analysis: Natively supports .h5ad, .h5, 10x CellRanger, and ParseBio outputs, enabling interactive and iterative analysis from initial QC and filtering through clustering, annotation, and trajectory analysis, with flexible workflows that adapt to your data at every stage.
  • Spatial Transcriptomics Analysis: Map gene expression in its native tissue context with full support for 10x Genomics Visium (Standard/HD) and Xenium. Visualize spatial cell distributions and identify spatially variable genes — all within the same environment used for single-cell RNA-seq, with no data export required.
  • Integrated Frameworks: Feeds directly into iPathwayGuide™ proprietary Impact Analysis methodology for mechanistic pathway analysis at single-cell resolution — connecting cell type annotation to pathway-level biological interpretation in a single workflow.
  • Cell-to-Cell Communication Analysis: Characterise intercellular signalling networks by identifying ligand-receptor interactions and communication patterns across cell types — revealing how cells coordinate behaviour within their native tissue environment.

"Single-cell and spatial analysis has been defined by fragmentation — too many tools, too many parameters, and no continuity between clustering and biological interpretation. The steep learning curve means critical know-how walks out the door every time an analyst leaves, and sharing results is harder than it should be," said Dr. Sorin Draghici, Founder and Chief Scientific Officer. "iSCanGuide replaces all of that with a single platform that takes researchers from count matrices to mechanistic pathway understanding — with sensible defaults, one-click sharing, and every setting captured. It connects directly to iPathwayGuide's proprietary Impact Analysis methodology, so the entire workflow runs in minutes rather than weeks."

To learn more about iSCanGuide, please visit our website.

About Advaita Bio

Advaita Bio builds AI-powered software for pathway analysis, variant interpretation, and single-cell analytics. Trusted by over 13,000 researchers and backed by nearly 20,000 peer-reviewed citations, the platform is built on two decades of scientifically validated algorithms to deliver biological insight that conventional tools miss.

Media contact

pr@advaitabio.com

Logo - https://mma.prnewswire.com/media/2974032/Advaita_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/advaita-bio-launches-iscanguide-unified-single-cell-and-spatial-transcriptomics-analysis-powered-by-gpu-accelerated-infrastructure-302764555.html

rt.gif?NewsItemId=EN52968&Transmission_Id=202605070745PR_NEWS_EURO_ND__EN52968&DateId=20260507


07.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2323312  07.05.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 22:30 Uhr • Artikel • dpa-AFX

Gestern 22:17 Uhr • Artikel • dpa-AFX

Gestern 22:05 Uhr • Artikel • dpa-AFX

Gestern 21:36 Uhr • Artikel • dpa-AFX

Gestern 21:17 Uhr • Artikel • dpa-AFX

Gestern 21:14 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer